Cortexyme to Present Preclinical and Clinical Data Supporting Its Novel Investigational Alzheimer’s Treatment At AD/PD 2019

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc., a privately held, clinical stage biopharmaceutical
company pioneering a novel disease-modifying therapeutic approach to
treat a key underlying cause of Alzheimer’s disease (AD) and other
degenerative diseases, today announced it will convene an educational
session at AD/PD™ 2019, the 14^th International Conference on
Alzheimer’s & Parkinson’s Diseases, which is taking place March 26-31 in
Lisbon, Portugal.

The session, “Treatment of a Bacterial Pathogen in Alzheimer’s Disease
Brains,” will be held on Wednesday, March 27, from 15:40-16:10 local
time in AD/PD 2019’s Auditorium I. During the program, Cortexyme
researchers will present data supporting a pathogenic role of Porphyromonas
gingivalis (P. gingivalis; Pg) in the development of
Alzheimer’s disease upstream from other disease targets, as well as the
rationale behind Cortexyme’s lead drug candidate, COR388, a
first-in-class, orally administered virulence factor inhibitor. P.
gingivalis was discovered in the brains of greater than 90 percent
of Alzheimer’s patients across multiple studies to date and has been
shown to be a driver of Alzheimer’s pathology in physiological animal
models, including amyloid beta production, neuroinflammation, and
neurodegeneration. Having successfully completed Phase 1b testing and
chronic toxicology studies, Cortexyme plans to take COR388 into a Phase
2/3 study, called the GAIN trial (GingipAIN inhibitor for treatment of
Alzheimer’s disease), starting in the second quarter of 2019.

“The bacterial hypothesis for Alzheimer’s pathogenesis certainly
provides an alternative to typical amyloid and tau targeting and, if
borne out in the clinic, would represent a major shift in how we think
about treating what has become one of medicine’s most vexing
challenges,” said Eric Siemers, M.D., chair of the session and a
longtime neurodegenerative disease expert who previously served at Eli
Lilly and Company for more than 19 years. “This session will review the
scientific rationale and data that support targeting Pg with a
novel bacterial protease inhibitor.”

The schedule for the session organized and supported by Cortexyme is as
follows:

“Cortexyme is pleased to contribute to the programming at AD/PD 2019 and
engage with other researchers and investigators around our novel
therapeutic in development, which we believe represents a new paradigm
for potential disease modification in Alzheimer’s disease,” said Casey
Lynch, Cortexyme’s co-founder and chief executive officer. “We look
forward to reviewing the data that supports COR388’s mechanism of
action, discussing the clinical results generated to date, and detailing
the design of our Phase 2/3 study now in the final stages of start-up.”

For more information about the industry supported educational session at
AD/PD 2019, visit the conference’s website.
For more information about Cortexyme’s GAIN trial, visit www.cortexyme.com/trials.

About Cortexyme, Inc.

Cortexyme is a privately held, clinical-stage pharmaceutical company
pioneering a novel disease-modifying therapeutic approach to treat a key
underlying cause of Alzheimer’s disease and other degenerative diseases.
Cortexyme is targeting a specific, infectious pathogen found in the
brain of Alzheimer’s patients and tied to neurodegeneration and
neuroinflammation in animal models. The company’s lead compound, COR388,
is beginning Phase 2/3 development in the second quarter of 2019; more
information can be found on ClinicalTrials.gov.
For more information on Cortexyme, visit www.cortexyme.com.

Contacts

Hal Mackins
For Cortexyme
[email protected]
(415)
994-0040